Citadel Advisors LLC increased its position in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 51.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,308 shares of the company’s stock after buying an additional 18,378 shares during the period. Citadel Advisors LLC’s holdings in Karyopharm Therapeutics were worth $521,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in KPTI. Teacher Retirement System of Texas bought a new position in Karyopharm Therapeutics during the fourth quarter worth $115,000. Voya Investment Management LLC raised its stake in Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Karyopharm Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after buying an additional 5,586 shares during the last quarter. New York State Common Retirement Fund raised its stake in Karyopharm Therapeutics by 33.6% during the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after buying an additional 7,099 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Karyopharm Therapeutics by 18.8% during the fourth quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after buying an additional 4,902 shares during the last quarter. 62.60% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on KPTI shares. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. initiated coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target for the company. ValuEngine downgraded shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. BidaskClub downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.11.
Shares of Karyopharm Therapeutics Inc (NASDAQ KPTI) opened at $16.86 on Friday. Karyopharm Therapeutics Inc has a 52 week low of $7.48 and a 52 week high of $16.93. The firm has a market cap of $795.47, a price-to-earnings ratio of -6.34 and a beta of 3.62.
ILLEGAL ACTIVITY WARNING: “Citadel Advisors LLC Has $521,000 Position in Karyopharm Therapeutics Inc (KPTI)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3252649/citadel-advisors-llc-has-521000-position-in-karyopharm-therapeutics-inc-kpti.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.